drugset / Trial / NCT02264158

Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers

NCT02264158

Phase 1 Completed 149 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Assessment of the influence of telmisartan, lacidipine and their combination on the QTC interval of the ECG

Timeline

Start
2001-09
Primary completion
2002-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lacidipine Small molecule 4 mg Oral
Comparator Lacidipine Small molecule 6 mg Oral
Subject Telmisartan Other / unclassified 40 mg Oral
Subject Telmisartan Other / unclassified 160 mg Oral

Indications

No indication recorded.